J.P. Morgan has initiated coverage of Haemonetics (NYSE:HAE) with an overweight rating, citing the potential for topline acceleration.
The investment bank said it viewed Haemonetics (HAE) as having “multiple shots on goal that should support a top-line acceleration and healthy